BeiGene
NEWS
BeiGene raised $3.3 billion on Shanghai’s STAR market, making it the first company to trade its shares in Shanghai, Hong Kong, and New York.
Roche announced promising results from the Phase II CITYSCAPE study of tiragolumab plus Tecentriq compared to Tecentriq alone as a treatment for PD-L1-positive metastatic NSCLC.
It’s been a busy week so far, with new discovery facilities launched in the biotech space.
Shoreline Biosciences secured $140 million in financing to accelerate the growth of its induced pluripotent stem cells (iPSC)-based immunotherapies and support the expansion of its manufacturing capabilities.
The U.S. Food and Drug Administration has a few PDUFA dates on its calendar for this week. Here’s a look.
FDA has been actively greenlighting a number of efforts over the last few days to push therapies for rare or serious diseases that have largely unmet medical needs. Here’s a look.
Brukinsa was approved for MSL patients who have received at least one anti-CD20-based regimen.
BeiGene plans to describe the power of its lung cancer portfolio at the European Society for Medical Oncology Congress 2021. The conference will run from September 16-21.
September is turning out to be a busy month for the U.S. Food and Drug Administration. Here’s a look at this week’s schedule for PDUFA dates.
JOBS
IN THE PRESS